ChromaDex (NASDAQ:CDXC) Downgraded to Buy Rating by StockNews.com

StockNews.com cut shares of ChromaDex (NASDAQ:CDXC) from a strong-buy rating to a buy rating in a report published on Tuesday morning.

A number of other research firms have also recently commented on CDXC. HC Wainwright boosted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. Roth Mkm lifted their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

ChromaDex Stock Down 2.4 %

Shares of CDXC opened at $6.00 on Tuesday. ChromaDex has a twelve month low of $1.34 and a twelve month high of $7.97. The stock has a market cap of $458.30 million, a PE ratio of 600.00 and a beta of 2.16. The business’s 50-day moving average price is $5.71 and its 200-day moving average price is $4.01.

ChromaDex (NASDAQ:CDXC) last posted its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the prior year, the company posted ($0.01) EPS. Analysts expect that ChromaDex will post 0.04 earnings per share for the current fiscal year.

Insider Transactions at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 9.64% of the company’s stock.

Institutional Trading of ChromaDex

A number of institutional investors have recently made changes to their positions in the stock. WINTON GROUP Ltd bought a new stake in ChromaDex during the 2nd quarter valued at $597,000. Bank of New York Mellon Corp increased its stake in shares of ChromaDex by 170.0% during the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after buying an additional 119,915 shares during the period. BSW Wealth Partners purchased a new position in ChromaDex during the 3rd quarter valued at $324,000. BNP Paribas Financial Markets raised its stake in ChromaDex by 1,885.7% in the third quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock worth $267,000 after buying an additional 69,582 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after purchasing an additional 62,692 shares during the period. Hedge funds and other institutional investors own 15.41% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.